Companies in #Small Molecule Therapeutics

Clinical-stage biotechnology company pioneering medicines that correct abnormal gene expression by targeting the chromatin regulatory system, including the BAF complex, for the treatment of cancer.

Remix Therapeutics is a clinical-stage biotechnology company developing small-molecule RNA-targeted therapeutics that modulate RNA processing. The company announced a reverse merger with Passage Bio in 2026 to take Passage's Nasdaq listing while advancing its lead mRNA degrader program.